| Literature DB >> 34646933 |
Anna M E Noten1, Janneke A E Kammeraad2, Nawin L Ramdat Misier1, Sip Wijchers1, Ingrid M van Beynum2, Michiel Dalinghaus2, Thomas B Krasemann2, Sing-Chien Yap1, Natasja M S de Groot1, Tamas Szili-Torok1.
Abstract
BACKGROUND: Catheter ablation (CA) is the first-choice treatment for tachyarrhythmia in children. Currently available CA techniques differ in mechanism of catheter navigation and energy sources. There are no large studies comparing long-term outcomes between available CA techniques in a pediatric population with atrioventricular reentry tachycardia (AVRT) or atrioventricular nodal reentry tachycardia (AVNRT) mechanisms.Entities:
Keywords: AP, accessory pathway; AVNRT, atrioventricular nodal reentry tachycardia; AVRT, atrioventricular reentry tachycardia; Atrioventricular nodal reentry tachycardia; Atrioventricular reentry tachycardia; CA, catheter ablation; CHD, congenital heart defect; CRYO, cryoablation; Catheter ablation; Cryoablation; DAP, dose area product; EAM, electro-anatomic mapping; ECG, electrocardiogram; MAN, manual; Pediatrics; RF, radiofrequency; RMN, remote magnetic navigation; Radiofrequency ablation; Remote magnetic navigation; SVT, supraventricular tachycardia; Supraventricular tachycardia
Year: 2021 PMID: 34646933 PMCID: PMC8495098 DOI: 10.1016/j.ijcha.2021.100881
Source DB: PubMed Journal: Int J Cardiol Heart Vasc ISSN: 2352-9067
Baseline demographic and clinical data.
| RMN N = 39 | MAN N = 12 | CRYO N = 28 | Total N = 79 | P-value | |
| Female | 22 (56.4%) | 7 (58.3%) | 16 (57.1%) | 45 (57.0%) | 0.99 |
| Age (year) | 15 (12–16) | 15 (12–17) | 14 (11–16) | 15 (12–16) | 0.53 |
| Weight (kg) | 62 (48–67) | 60 (49–67) | 53 (43–64) | 59 (48–66) | 0.25 |
| Length (cm) | 169 (161–177) | 167 (158–172) | 164 (154–175) | 166 (158–175) | 0.33 |
| BMI (kg/m2) | 21 (19–23) | 22 (18–23) | 19 (17–21) | 20 (18–22) | 0.19 |
| Palpitations | 39 (100.0%) | 12 (100.0%) | 28 (100.0%) | 79 (100.0%) | ns |
| Syncope | 1 (2.6%) | 0 (0.0%) | 1 (3.6%) | 2 (2.5%) | 0.81 |
| Family History Arrhythmias | 3 (7.7%) | 0 (0.0%) | 2 (7.1%) | 5 (6.3%) | 0.62 |
| Family History Sudden death | 1 (2.6%) | 1 (8.3%) | 0 (0.0%) | 2 (2.5%) | 0.31 |
| Beta-blocker | 1 (2.6%) | 0 (0.0%) | 2 (7.1%) | 3 (3.8%) | 0.47 |
| Sotalol | 6 (15.4%) | 3 (25.0%) | 6 (21.4%) | 15 (19.0%) | 0.70 |
| Digoxine | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | ns |
| Verapamil | 2 (5.1%) | 0 (0.0%) | 3 (10.7%) | 5 (6.3%) | 0.40 |
| Flecainide | 0 (0.0%) | 1 (8.3%) | 0 (0.0%) | 1 (1.3%) | 0.06 |
| RMN N = 69 | MAN N = 64 | Cryo N = 11 | Total N = 144 | P-value | |
| Female | 31 (44.9%) | 31 (48.4%) | 4 (36.4%) | 66 (45.8%) | 0.74 |
| Age (year) | 14 (12–16) | 15 (12–17) | 14 (11–16) | 14 (12–16) | 0.48 |
| Weight (kg) | 53 (42–65) | 57 (49–65) | 53 (43–64) | 56 (45–65) | 0.65 |
| Length (cm) | 165 (155–177) | 170 (158–180) | 164 (154–175) | 167 (156–177) | 0.44 |
| BMI (kg/m2) | 19 (18–22) | 20 (18–21) | 19 (17–21) | 19 (18–21) | 0.98 |
| Palpitations | 62 (89.9%) | 57 (90.5%) | 11 (100.0%) | 130 (90.9%) | 0.55 |
| Syncope | 6 (8.7%) | 4 (6.3%) | 1 (9.1%) | 11 (7.7%) | 0.87 |
| Asymptomatic | 6 (8.7%) | 8 (12.5%) | 0 (0.0%) | 14 (9.7%) | 0.40 |
| Family History Arrhythmias | 11 (16.2%) | 5 (7.9%) | 2 (18.2%) | 18 (12.7%) | 0.31 |
| Family History Sudden death | 5 (7.5%) | 2 (3.2%) | 0 (0.0%) | 7 (5.0%) | 0.39 |
| Beta-blocker | 2 (2.9%) | 1 (1.6%) | 1 (9.1%) | 4 (2.8%) | 0.37 |
| Sotalol | 10 (14.5%) | 12 (18.8%) | 6 (54.5%) | 28 (19.4%) | |
| Digoxine | 1 (1.4%) | 0 (0.0%) | 0 (0.0%) | 1 (0.7%) | 0.58 |
| Verapamil | 5 (7.2%) | 0 (0.0%) | 1 (9.1%) | 6 (4.2%) | 0.08 |
| Flecainide | 1 (1.4%) | 0 (0.0%) | 0 (0.0%) | 1 (0.7%) | 0.58 |
BMI: body mass index, CRYO: manual guided cryoablation, MAN: manual-guided radiofrequency ablation, RMN: remote magnetic navigation guided radiofrequency ablation.
Asymptomatic patients in whom accidentally a WPW pattern on 12-lead ECG was discovered at a (e.g. sport or profession related) regular medical check-up.
Procedural parameters.
| RMN N = 39 | MAN N = 12 | CRYO N = 28 | Total N = 79 | P-value | |
| Typical (slow-fast) | 33 (84.5%) | 11 (91.7%) | 26 (92.9%) | 70 (88.6%) | 0.54 |
| Atypical (slow–slow) | 1 (2.6%) | 0 (0.0%) | 1 (3.6%) | 2 (2.5%) | 0.81 |
| Atypical (fast–slow) | 2 (5.1%) | 0 (0.0%) | 1 (3.6%) | 3 (3.8%) | 0.72 |
| Empirical slow pathway ablation | 3 (7.7%) | 1 (8.3%) | 0 (0.0%) | 4 (5.1%) | 0.31 |
| Procedure time (min) | 101 (87–121)* | 88 (62–99)* | 120 (88–143)* | 101 (85–128) | |
| Fluoroscopy dose (mGy) | 30 (20–41)** | 27 (17–77)** | 45 (29–65)** | 33 (21–51) | |
| Ablation time (sec) | 193 (104–322)*** | 352 (88–711)*** | 572 (480–932)*** | 279 (118–609) | |
| Application number | 5 (2–10) | 3 (2–10) | 3 (2–5) | 4 (2–7) | 0.15 |
| Acute success | 39 (100.0%) | 12 (100.0%) | 24 (85.7%) | 75 (94.9%) | |
| RMN N = 69 | MAN N = 64 | Cryo N = 11 | Total N = 144 | P-value | |
| Concealed AP | 26 (37.7%) | 24 (37.5%) | 8 (72.7%) | 58 (40.3%) | 0.07 |
| WPW | 43 (62.3%) | 40 (62.5%) | 3 (27.3%) | 86 (59.7%) | 0.07 |
| LA free wall | 46 (66.7%) | 36 (56.3%) | 0 (0.0%) | 82 (56.9%) | |
| RA free wall | 8 (11.6%) | 3 (4.7%) | 0 (0.0%) | 11 (7.6%) | 0.20 |
| Septal | 13 (18.8%) | 20 (31.2%) | 3 (27.3%) | 36 (25.0%) | 0.25 |
| Parahisian | 2 (2.9%) | 0 (0.0%) | 7 (63.6%) | 9 (6.3%) | |
| Multiple AP | 0 (0.0%) | 5 (7.8%) | 1 (9.1%) | 6 (4.2%) | 0.06 |
| Procedure time (min) | 105 (88–135) | 100 (81–160) | 150 (107–183) | 105 (83–143) | 0.15 |
| Fluoroscopy dose (mGy) | 42 (26–61) | 55 (32–85) | 57 (39–98) | 48 (30–81) | 0.07 |
| Ablation time (sec) | 157 (78–365) | 195 (74–409) | 480 (300–691) | 180 (78–415) | 0.05 |
| Application number | 3 (1–9) | 5 (2–12) | 2 (2–6) | 4 (2–10) | 0.36 |
| Acute success | 68 (98.6%) | 61 (95.3%) | 9 (81.8%) | 138 (95.8%) | |
| Disappearance of pre-excitation on ECG (if present pre-procedural) | 41 (97.6%) | 39 (95.1%) | 3 (100.0%) | 83 (96.5%) | 0.78 |
Post-hoc pairwise comparison using the Dunn-Bonferroni approach:
* Procedure time: RMN versus MAN P = 0.028; MAN versus CRYO P = 0.005; RMN versus CRYO P = 0.029.
** Fluoroscopy dose: RMN versus MAN P = 0.71; MAN versus CRYO P = 0.17; RMN versus CRYO P = 0.012.
*** Ablation time: RMN versus MAN P = 0.37; MAN versus CRYO P = 0.12; RMN versus CRYO P < 0.001.
AP: accessory pathway, AVNRT: atrioventricular nodal reentry tachycardia, AVRT: atrioventricular reentry tachycardia, CRYO: manual guided cryoablation, LA: left atrium, MAN: manual-guided radiofrequency ablation, RA: right atrium, RMN: remote magnetic navigation guided radiofrequency ablation, WPW: Wolff-Parkinson-White
Fig. 1Procedural parameters. Mean and interquartile range of three procedural parameters: procedure time, fluoroscopy dose and ablation time. Significant results of the Post-hoc pairwise comparison using the Dunn-Bonferroni approach are marked with an asterisk (*): AVNRT procedure time: RMN versus MAN P = 0.028; MAN versus CRYO P = 0.005; RMN versus CRYO P = 0.029. AVNRT Fluoroscopy dose: RMN versus CRYO P = 0.012. AVNRT Ablation time: RMN versus CRYO P < 0.001. AVNRT: atrioventricular nodal reentry tachycardia, AVRT: atrioventricular reentry tachycardia, CRYO: manual guided cryoablation, MAN: manual-guided radiofrequency ablation, RMN: remote magnetic navigation guided radiofrequency ablation.
Long-term outcomes.
| RMN | MAN | CRYO | Total | P-value | |
| Recurrence | 3 (7.7%) | 1 (8.3%) | 10 (35.7%) | 14 (17.7%) | |
| Time to Recurrence (mo) | 2 (1–2) | 12 (12–12) | 6 (1–13) | 6 (1–12) | 0.49 |
| Recurrence of other arrhythmia | 2 (5.1%) | 1 (8.3%) | 1 (3.6%) | 4 (5.1%) | 0.82 |
| Redo | 2 (5.1%) | 1 (8.3%) | 9 (32.1%) | 12 (15.2%) | |
| RMN | MAN | CRYO | Total | P-value | |
| Recurrence | 3 (4.3%) | 10 (15.6%) | 6 (54.5%) | 19 (13.2%) | |
| Time to recurrence (mo) | 16 (1–88) | 1 (0–29) | 6 (1–41) | 2 (1–30) | 0.33 |
| Recurrence of other arrhythmia | 3 (4.3%) | 1 (1.6%) | 0 (0.0%) | 4 (2.8%) | 0.52 |
| Redo | 5 (7.2%) | 9 (14.1%) | 5 (45.5%) | 19 (13.2%) | |
AVNRT: atrioventricular nodal reentry tachycardia, AVRT: atrioventricular reentry tachycardia, CRYO: manual guided cryoablation, MAN: manual-guided radiofrequency ablation, MO: months, RMN: remote magnetic navigation guided radiofrequency ablation
Fig. 2Recurrence rates - cumulative hazard on arrhythmia recurrence. Display of the cumulative hazard on atrioventricular nodal reentry tachycardia (AVNRT) - and atrioventricular reentry tachycardia (AVRT) recurrence, compared between three techniques: remote magnetic navigation guided radiofrequency ablation (RMN), manual guided radiofrequency ablation (MAN) and manual guided cryoablation (CRYO).
Subanalysis of ablation of septal and parahisian located AP.
| RMN | MAN | CRYO | Total | P-value | |
|---|---|---|---|---|---|
| Acute success | 14 (93.3%) | 18 (90.0%) | 8 (80.0%) | 40 (88.9%) | 0.57 |
| Recurrence | 2 (13.3%) | 6 (30.0%) | 6 (60.0%) | 14 (31.1%) | |
| Redo | 1 (6.7%) | 5 (25.0%) | 5 (50.0%) | 11 (24.4%) |
AP: accessory pathway, CRYO: manual guided cryoablation, MAN: manual-guided radiofrequency ablation, RMN: remote magnetic navigation guided radiofrequency ablation